Literature DB >> 6533297

Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. I. Derivations and theoretical analysis.

P Veng-Pedersen.   

Abstract

The approach presented enables a model independent representation of the pharmacokinetics of drugs with a liner disposition and some drugs with a nonlinear disposition. The approach is based on a decomposition of the drug disposition into an elimination function q(c) and a distribution function h(t). The q function represents the net effect of all disposition processes which work toward a reduction in the systemic drug level. The h function represents the net effect of all disposition processes which slow down the rate of decline of the systemic drug level by returning drug from the peripheral environment to the systemic circulation. Several theorems relating q and h to the drug disposition are presented which uniquely define these functions mathematically. The disposition decomposition is of particular significance in three main areas of pharmacokinetics: (1) evaluation of drug absorption, (2) drug level predictions including steady state predictions, (3) and elucidation of drug disposition kinetics. The practical significance of the decomposition method in these three areas is discussed, and various procedures for the application of the method are proposed. The decomposition method represents a model independent alternative to pharmacokinetic models such as linear compartmental models, the recirculation model, and some physiologic models. This also includes nonlinear forms of such models, as long as the nonlinearity is due to a central nonlinear elimination. The greatest promise and significance of the disposition decomposition approach appears to be its application to nonlinear pharmacokinetics. In contrast to linear pharmacokinetics the kinetic analysis in such cases has been limited to model dependent methods employing specific pharmacokinetic models, due to the lack of model independent alternatives. The novel development presented offers such alternatives. For some applications these alternatives appear more rational in the sense that the analysis becomes more general and objective and may be based on fewer assumptions.

Mesh:

Substances:

Year:  1984        PMID: 6533297     DOI: 10.1007/bf01059557

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  12 in total

1.  Nonlinear assessment of phenytoin bioavailability.

Authors:  W J Jusko; J R Koup; G Alván
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

2.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  A linear recirculation model for drug disposition.

Authors:  D J Cutler
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

4.  Transfer times across the human body.

Authors:  C Waterhouse; J Keilson
Journal:  Bull Math Biophys       Date:  1972-03

5.  Preliminary model for methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko
Journal:  J Pharm Sci       Date:  1970-02       Impact factor: 3.534

6.  Linear systems analysis in pharmacokinetics.

Authors:  D J Cutler
Journal:  J Pharmacokinet Biopharm       Date:  1978-06

7.  An algorithm and computer program for deconvolution in linear pharmacokinetics.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

8.  Pharmacokinetic analysis by linear system approach I: cimetidine bioavailability and second peak phenomenon.

Authors:  P Veng Pedersen
Journal:  J Pharm Sci       Date:  1981-01       Impact factor: 3.534

9.  Model-independent method of analyzing input in linear pharmacokinetic systems having polyexponential impulse response I: Theoretical analysis.

Authors:  P V Pedersen
Journal:  J Pharm Sci       Date:  1980-03       Impact factor: 3.534

10.  Phenytoin: pharmacokinetics and bioavailability.

Authors:  R Gugler; C V Manion; D L Azarnoff
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

View more
  15 in total

1.  Dynamics of drug distribution. I. Role of the second and third curve moments.

Authors:  M Weiss; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

Review 2.  Noncompartmental versus compartmental modelling in clinical pharmacokinetics.

Authors:  W R Gillespie
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 3.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

4.  Mean residence times and distribution volumes for drugs undergoing linear reversible metabolism and tissue distribution and linear or nonlinear elimination from the central compartments.

Authors:  H Y Cheng; W J Jusko
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

5.  A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination.

Authors:  P Veng-Pedersen; J A Widness; J Wang; R L Schmidt
Journal:  J Pharmacokinet Biopharm       Date:  1997-10

6.  A semiparametric approach to physiological flow models.

Authors:  D Verotta; L B Sheiner; W F Ebling; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1989-08

7.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

8.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. IV. Exact relationship between the terminal log-linear slope parameter beta and drug clearance.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

9.  Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations.

Authors:  P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

10.  Drug disposition analysis: a comparison between budesonide and fluticasone.

Authors:  Anders Källén; Lars Thorsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.